Screener
ANI Pharmaceuticals ANIP Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
FAQ
- What is ANI Pharmaceuticals's restricted cash?
- ANI Pharmaceuticals (ANIP) reported restricted cash of $35K in Q2 2026.
- What is the long-term trend for ANI Pharmaceuticals's restricted cash?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's restricted cash has grown at a -62.7% compound annual growth rate (CAGR), from $5M to $36K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about ANI Pharmaceuticals's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude